Researchers at Washington University School of Medicine in St. Louis published the results of a clinical trial evaluating an antidepressant, fluvoxamine, for early treatment for Covid-19.
Gilead remdesivir study finds only marginal benefit for moderate COVID-19 patients (Reuters) – Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc’s (GILD.O) remdesivir, but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data. The drug, […]
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A protein called ACE2 is intimately involved in how SARS-CoV-2, the virus that causes COVID-19, infects the body.
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name: COVID-19. The most recent figures indicate there are more than 45,000 infections worldwide and the virus has killed more than 1,100 people.
U.S. researchers who conducted the largest study yet into whether applying powder to the genitals increases a woman’s risk of ovarian cancer were unable to definitively put to rest the issue that has prompted thousands of lawsuits against Johnson & Johnson and other companies.